Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease

NCT01306929 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
134
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Prilenia